- Capmatinib, a selective reversible inhibitor of MET tyrosine kinase, demonstrated effective antitumor activity in patients with advanced NSCLC and a MET exon 14 skipping mutation, especially those who were previously untreated.
Why this matters
- Capmatinib is the first approved treatment for NSCLC with a MET exon 14 skipping mutation.
- Prospective, international, multiple-cohort, phase 2 GEOMETRY study.
- 364 patients with advanced NSCLC received capmatinib.
- Funding: Novartis Pharmaceuticals.
- 97 patients had a MET exon 14 skipping mutation, and 210 had MET amplification.
- Results in the MET exon 14 skipping mutation group:
- Overall response was reported in 41% of previously treated patients and 68% of previously untreated patients (median duration of response, 9.7 and 12.6 months, respectively).
- Median PFS was 5.4 months among previously treated patients and 12.4 months among previously untreated patients.
- Results in MET amplification group:
- Efficacy was limited in previously treated patients with MET amplification who had a gene copy number of
- Among patients with a gene copy number of ≥10, overall response was reported in 29% of previously treated patients and 40% of previously untreated patients (median duration of response, 8.3 months and 7.5 months, respectively).
- Grade 3-4 adverse events (AEs) reported in 67% of patients and serious AEs reported in 13%.
- Open-label study.